Announcements Trials
Browse Landscape Eligibility

Clinical Trials

8 trials
RecentStart dateEnrollment
CRC × Clear all

Phase

Phase 1/2 3Phase 2 2Phase NA 1

Status

Unknown 3Not yet recruiting 2Withdrawn 1Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 5INDUSTRY 3

Study Type

Interventional 6Observational 2

Sponsor

Cancer Type

Thoracic 1

Conditions

Breast Neoplasms 10998Neoplasms 8807Carcinoma, Non-Small-Cell Lung 5711Prostatic Neoplasms 5278Colorectal Neoplasms 4951Lung Neoplasms 4210Pancreatic Neoplasms 3003Multiple Myeloma 3001Neoplasm Metastasis 2954Leukemia, Myeloid, Acute 2927Carcinoma, Hepatocellular 2734Ovarian Neoplasms 2657Melanoma 2635Stomach Neoplasms 2567Lymphoma 2502Head and Neck Neoplasms 2162Recurrence 2132Precursor Cell Lymphoblastic Leukemia-Lymphoma 2069Leukemia 1992Brain Neoplasms 1971Colonic Neoplasms 1939Lymphoma, Non-Hodgkin 1894Rectal Neoplasms 1846Uterine Cervical Neoplasms 1806Glioblastoma 1699Leukemia, Lymphocytic, Chronic, B-Cell 1663Carcinoma, Renal Cell 1597Squamous Cell Carcinoma of Head and Neck 1550Lymphoma, Follicular 1526Esophageal Neoplasms 1516

Interventions

Cetuximab 2camrelizumab 1Oxaliplatin 1Leucovorin 1Irinotecan 1HLX07 1Folfox protocol 1Fluorouracil 1CCT239065 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements
NCT07283367 2025-12-15

A Phase Ib/II Trial of HS-20110 Combination Therapies in Advanced Colorectal Cancer Patients.

Hansoh BioMedical R&D Company

Phase 1/2 Not yet recruiting
502 enrolled

CRC

NCT07204574 2025-10-02

The Phase 1b/IIa, Open-label, Dose Escalation and Dose Expansion to Evaluate Safety, Tolerability, and Preliminary Efficacy of the Combination of HCB101, Cetuximab/Bevacizumab, and FOLFOX/FOLFIRI in Advanced or Metastatic Colorectal Cancer

Chang Gung Memorial Hospital

Phase 1/2 Recruiting
40 enrolled

CRC

NCT03336658 2024-11-13

ITB

Insel Gruppe AG, University Hospital Bern

Active not recruiting
150 enrolled

CRC

NCT04984369 2023-08-21

The Efficacy of HLX208 (BRAF V600E Inhibitor) With Cetuximab for Metastatic Colorectal Cancer (mCRC) With BRAF V600E Mutation After First-line Treatment

Shanghai Henlius Biotech

Phase 2 Unknown
50 enrolled

CRC

NCT05314309 2023-01-11

mtFIT

The Netherlands Cancer Institute

Unknown
14,712 enrolled

CRC

NCT05239650 2022-05-03

Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07+HLX10 +mFOLFOX6 or HLX07 Monotherapy in Patients With mCRC

Shanghai Henlius Biotech

Phase 2 Not yet recruiting
50 enrolled

CRC

NCT03337776 2021-08-05

Effect of WhatsApp Messenger on Uptake of CRC Screening Study

Chinese University of Hong Kong

Phase NA Withdrawn

CRC

NCT03601598 2018-07-26

A Trial of SHR-1210 in Combination With SHR6390 in Patients With Advanced CRC, NSCLC and HCC

Harbin Medical University

Phase 1/2 Unknown
41 enrolled
Thoracic

CRC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡